Literature DB >> 12413422

Adeno-associated virus vectors for gene transfer to the brain.

Takashi Okada1, Tatsuya Nomoto, Kuniko Shimazaki, Wang Lijun, Yanyan Lu, Takashi Matsushita, Hiroaki Mizukami, Masashi Urabe, Yutaka Hanazono, Akihiro Kume, Shin-ichi Muramatsu, Imaharu Nakano, Keiya Ozawa.   

Abstract

Gene therapy is a novel method under investigation for the treatment of neurological disorders. Considerable interest has focused on the possibility of using viral vectors to deliver genes to the central nervous system. Adeno-associated virus (AAV) is a potentially useful gene transfer vehicle for neurologic gene therapies. The advantages of AAV vector include the lack of any associated disease with a wild-type virus, the ability to transduce nondividing cells, the possible integration of the gene into the host genome, and the long-term expression of transgenes. The development of novel therapeutic strategies for neurological disorder by using AAV vector has an increasing impact on gene therapy research. This article describes methods that can be used to generate rodent and nonhuman primate models for testing treatment strategies linked to pathophysiological events in the ischemic brain and neurodegenerative disorders such as Parkinson's disease. Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Year:  2002        PMID: 12413422     DOI: 10.1016/s1046-2023(02)00228-1

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  8 in total

1.  The impact of molecular manipulation in residue 114 of human immunodeficiency virus type-1 reverse transcriptase on dNTP substrate binding and viral replication.

Authors:  Sarah K Van Cor-Hosmer; Waaqo Daddacha; Z Kelly; Amy Tsurumi; Edward M Kennedy; Baek Kim
Journal:  Virology       Date:  2011-12-05       Impact factor: 3.616

Review 2.  Therapeutic gene silencing in neurological disorders, using interfering RNA.

Authors:  G Scott Ralph; Nicholas D Mazarakis; Mimoun Azzouz
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

3.  Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.

Authors:  Jean-Charles Paterna; Joram Feldon; Hansruedi Büeler
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 4.  Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Authors:  H Akiko Popiel; Toshihide Takeuchi; James R Burke; Warren J Strittmatter; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

5.  Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance.

Authors:  Liang Yang; Karen A Scott; Jayson Hyun; Kellie L Tamashiro; Nancy Tray; Timothy H Moran; Sheng Bi
Journal:  J Neurosci       Date:  2009-01-07       Impact factor: 6.167

6.  Differential expression of secreted phosphoprotein 1 in the motor cortex among primate species and during postnatal development and functional recovery.

Authors:  Tatsuya Yamamoto; Takao Oishi; Noriyuki Higo; Shigeo Murayama; Akira Sato; Ichiro Takashima; Yoko Sugiyama; Yukio Nishimura; Yumi Murata; Kimika Yoshino-Saito; Tadashi Isa; Toshio Kojima
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 7.  Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence.

Authors:  Arianna Manini; Elena Abati; Andi Nuredini; Stefania Corti; Giacomo Pietro Comi
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

8.  Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.

Authors:  H Akiko Popiel; Toshihide Takeuchi; Hiromi Fujita; Kazuhiro Yamamoto; Chiyomi Ito; Hiroshi Yamane; Shin-ichi Muramatsu; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.